Therefore, compared with CTRL-not-α-mIL2, CD8+ T-cell cis-targeted IL2 shows a superior ability to increase the numbers and functionality of intratumoral antigen-specific CD8+ T cells in multiple tumor models. This evidence concerns the gene CD8A and neoplasm.